Enhancing Medicare and FDA Regulations for Better Patient Outcomes

In a recent session held in Washington, D.C., Congressman Morgan Griffith chaired the Subcommittee on Health during the markup of key public health legislation. This legislative package, discussed in a bipartisan manner, aims to enhance regulatory oversight and improve patient outcomes by addressing challenges within Medicare and the FDA's regulatory framework.

Key pieces of legislation, advanced by voice vote to the full committee, include H.R. 4348, the Kay Hagan Tick Act reauthorization, and H.R. 2821, the FDA Modernization Act 3.0. The latter seeks to implement modern, alternative methods to animal testing in drug development. H.R. 1703, the Choices for Increased Mobility Act of 2025, aims to facilitate easier access to lightweight wheelchairs for Medicare recipients, addressing restrictive policies on durable medical equipment.

Congressman Buddy Carter emphasized the critical role of innovative approaches in drug development brought forward by the FDA Modernization Act 3.0. Meanwhile, Congressman John Joyce advocates for legislative measures that enhance Medicare beneficiaries' mobility options. Additionally, Congressman Troy Balderson underscored the importance of H.R. 3747 in enhancing Alzheimer's provider training, especially in rural areas, aligning with the increasing prevalence of dementia. The Subcommittee's efforts reflect a strong commitment to improving healthcare services and regulatory processes for better patient outcomes.